Trial Profile
An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Oct 2023
Price :
$35
*
At a glance
- Drugs Tagitanlimab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 19 Oct 2023 Status has been to completed.
- 17 Jul 2018 New trial record